MIM Pharma’s work is rooted in more than a decade of research on plant-derived active compounds and their interaction with complex human biological systems. Our R&D teams have contributed to peer-reviewed publications on antiviral and immune-supportive formulations in major scientific outlets, including journals published by Elsevier.
During recent global health challenges, our innovation platform was used to investigate combinations of standardized medicinal plant constituents with potential to support antiviral defense and immune resilience. These studies – together with our ongoing work on migraine, respiratory balance, rhinitis and seasonal allergy – form the scientific backbone for the SinaVita® product family.
Our approach focuses on:
understanding how networks of bioactive compounds interact with human physiology
translating this knowledge into reproducible, standardized formulations
developing MDR-compliant Class I medical devices and dietary supplements that support key physiological functions.
Our goal is to make high-quality, evidence-informed solutions accessible through pharmacies, distributors, and healthcare partners across Europe and beyond.
We combine medicinal plant science, AI-driven data analysis and ISO-certified manufacturing in Norway to deliver clinically oriented, pharmacy-ready products.
MIM Pharma’s research and development journey began in 2013, driven by a simple but ambitious idea: to bridge the gap between traditional medicinal plant knowledge and modern pharmaceutical standards. Since then, our team has grown into an international group of biochemists, clinicians, engineers and industry executives with experience from leading universities and healthcare systems.
Using a systems-biology approach, we analyse how hundreds of plant-derived compounds interact with human protein networks, signaling pathways and organ systems. By combining this with AI, advanced data mining and controlled extraction processes, we design formulations that are standardized, reproducible and suitable for medical-device and dietary-supplement frameworks.
Today, MIM Pharma develops and manufactures the SinaVita® product families – targeting migraine support, respiratory balance, immune resilience and allergy-related discomfort. Production is carried out in Norway under ISO 13485, ISO 22000 and ISO 9001, with MDR-compliant medical devices registered in EUDAMED and ready for European distribution.
MIM Pharma’s leadership team brings together experienced biopharma experts, clinicians, researchers and industry executives with backgrounds from leading European and international institutions. Our team combines deep expertise in medicinal plant chemistry, systems-biology based formulation engineering, medical device compliance and ISO-certified manufacturing.
With a strong focus on migraine, respiratory balance, immune resilience and seasonal allergy, our R&D and product development teams have played a central role in designing the SinaVita® formulation platform and preparing our MDR medical devices and dietary supplements for European market distribution.
The management group reflects more than a decade of coordinated research, technical execution and commercialization experience. Together, we are committed to delivering high-quality, well-documented and accessible healthcare solutions across pharmacies, distributors and international partners.
CHIEF EXECUTIVE OFFICER
CHIEF SCIENTIFIC OFFICER
CHIEF FINANCIAL OFFICER
CHIEF SAFETY AND COMPLIANCE OFFICER
DIRECTOR OF CLINICAL OPERATIONS
SALES & MARKETING DIRECTOR
Chief Scientific and Research Consultant
Chief Scientific and Research Consultant
Research & Development
